SOD1 and amyotrophic lateral sclerosis: In vitro studies have demonstrated that ADSC-derived EVs can alter the cellular phenotype of amyotrophic lateral sclerosis (ALS), including reducing aggregation of superoxide dismutase 1 and improving mitochondrial function, indicating their potential therapeutic use in ALS [92].